Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Abstract

Women with mutations in BRCA1 or BRCA2 are at tremendously increased lifetime risk of both breast and BRCA-associated gynecologic (ovarian, fallopian tube, and primary peritoneal) cancer. Because of limitations in the efficacy of available screening and chemopreventive approaches for women with a mutation in one of these genes, surgical risk reduction, particularly risk-reducing salpingo-oophorectomy (RRSO), has become an important component of the management options in hereditary breast-ovarian cancer syndrome. This article will review the rationale and efficacy of RRSO for prevention of breast and BRCA-associated gynecologic cancer. Surgical technique and methods of pathologic evaluation will be presented. Controversies regarding uterine preservation and post-RRSO hormone replacement therapy will be addressed. Considerations that may impact the appropriate timing of the procedure will be reviewed, and the potential role of RRSO in BRCA-negative hereditary breast cancer families will also be discussed.

• Authors: Noah D Kauff, Richard R Barakat
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 25 Issue 20 Pg. 2921-7 (Jul 10 2007) ISSN: 1527-7755 [Electronic] United States
• PMID: 17617523 (Publication Type: Journal Article, Review)

Chemical References

• BRCA1 Protein
• BRCA2 Protein

Topics

• BRCA1 Protein (genetics)
• BRCA2 Protein (genetics)
• Breast Neoplasms (genetics)
• DNA Mutational Analysis
• Female
• Genes, BRCA1
• Genes, BRCA2
• Germ-Line Mutation
• Humans
• Models, Anatomic
• Ovarian Neoplasms (genetics)
• Ovariectomy (instrumentation, methods)
• Risk